

Francescopaolo Antonucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8395333/publications.pdf>

Version: 2024-02-01

30
papers

148
citations

1683354

5
h-index

1199166

12
g-index

31
all docs

31
docs citations

31
times ranked

561
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiclass HCV resistance to direct acting antiviral failure in real life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017, 37, 514-528.	1.9	84
2	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 739-750.	1.3	13
3	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. <i>PLoS ONE</i> , 2017, 12, e0177352.	1.1	13
4	Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders. <i>Infectious Diseases</i> , 2022, 54, 241-246.	1.4	8
5	HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 1986-1998.	1.9	6
6	Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. <i>Digestive and Liver Disease</i> , 2015, 47, 157-163.	0.4	5
7	Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. <i>Digestive and Liver Disease</i> , 2015, 47, 233-241.	0.4	4
8	HCV-RNA quantification in liver biptic samples and extrahepatic compartments, using the abbott Real Time HCV assay. <i>Journal of Virological Methods</i> , 2017, 246, 1-7.	1.0	2
9	Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies. <i>Journal of Hepatology</i> , 2017, 66, S82-S83.	1.8	2
10	The microbiological profile of patients with Fournier's gangrene: A retrospective multi-institutional cohort study. <i>Urologia</i> , 2021, , 039156032110184.	0.3	2
11	Evaluation of a potential prognostic parameter for the inflammatory status in COVID-19 patients: The Inflammatory Protein Ratio. <i>Electrophoresis</i> , 2022, , .	1.3	2
12	63 CORRELATION OF EARLY DETECTION OF HCV NS3-RESISTANCE AND VIROLOGICAL FAILURE IN PATIENTS TREATED WITH TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR. <i>Journal of Hepatology</i> , 2013, 58, S29.	1.8	1
13	P0915 : Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing. <i>Journal of Hepatology</i> , 2015, 62, S688.	1.8	1
14	Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment. <i>Digestive and Liver Disease</i> , 2016, 48, e3-e4.	0.4	1
15	In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment. <i>Journal of Hepatology</i> , 2016, 64, S419-S420.	1.8	1
16	Different Prevalence of HCV Resistance and HCV RNA Quantification Within Tumoral and Non Tumoral Liver Tissues in HCC/Transplanted Patients. <i>Journal of Hepatology</i> , 2016, 64, S416-S417.	1.8	1
17	Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2193-2195.	1.1	1
18	Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies. <i>Digestive and Liver Disease</i> , 2017, 49, e49-e50.	0.4	1

#	ARTICLE	IF	CITATIONS
19	166 HCV DIVERSITY AND FIBROSIS PROGRESSION: NS5A AND CORE VARIANTS CORRELATE WITH SEVERITY OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2013, 58, S74.	1.8	0
20	OC-24 Genotype analysis, at baseline and early time-points, by population and ultra-deep sequencing in HCV patients treated with BOC/TVR-based therapy. <i>Digestive and Liver Disease</i> , 2013, 45, S8-S9.	0.4	0
21	Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitors. <i>Digestive and Liver Disease</i> , 2014, 46, e45.	0.4	0
22	P1236 NS3, NS5A AND NS5B COEVOLUTION DURING TREATMENT WITH FIRST-GENERATION PROTEASE INHIBITORS. <i>Journal of Hepatology</i> , 2014, 60, S501.	1.8	0
23	P1235 BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS. <i>Journal of Hepatology</i> , 2014, 60, S500-S501.	1.8	0
24	Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?. <i>Digestive and Liver Disease</i> , 2014, 46, e47-e48.	0.4	0
25	Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors. <i>Digestive and Liver Disease</i> , 2015, 47, e48.	0.4	0
26	P0912 : Early-phase HCV kinetics and role of pre-existing resistance in cirrhotic or interferon-insensitive patients on daclatasvir plus asunaprevir. <i>Journal of Hepatology</i> , 2015, 62, S686-S687.	1.8	0
27	Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents. <i>Digestive and Liver Disease</i> , 2016, 48, e1-e2.	0.4	0
28	Different prevalence of HCV resistance and HCV quantification within blood and liver samples (tumoral and non tumoral tissues) of HCC/transplanted patients. <i>Digestive and Liver Disease</i> , 2016, 48, e56.	0.4	0
29	Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy. <i>Digestive and Liver Disease</i> , 2017, 49, e62-e63.	0.4	0
30	HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life. <i>Digestive and Liver Disease</i> , 2017, 49, e53.	0.4	0